On May 6, 2020 Boston Scientific Corporation (NYSE: BSX) reported that it will participate in three upcoming virtual investor conferences (Press release, Boston Scientific, MAY 6, 2020, View Source [SID1234557193]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 13, 2020, Dan Brennan, executive vice president and chief financial officer, and Susie Lisa, vice president, Investor Relations, will participate in a 30-minute question-and-answer session with the host analyst at the BofA Securities 2020 Health Care Conference. The session will begin at approximately 8:20 a.m. EDT.

On May 19, 2020, Jeff Mirviss, executive vice president and president, Peripheral Interventions, Michael Jaff, D.O., vice president, clinical affairs, innovation and technology, Peripheral Interventions, and Susie Lisa will participate in a 40-minute question-and-answer session with the host analyst at the UBS Global Healthcare Conference. The session will begin at approximately 9:10 a.m. EDT.

On May 27, 2020, Mike Mahoney, chairman and chief executive officer, and Susie Lisa will participate in a 50-minute question-and-answer session with the host analyst at Bernstein’s 36th Annual Strategic Decisions Conference. The session will begin at approximately 8 a.m. EDT.

A live webcast and replay of the webcast for each event will be accessible at investors.bostonscientific.comView Source The replay will be available beginning approximately one hour following the completion of each event.

On May 6, 2020 Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, reported that interim phase I clinical data from the phase I/II trial evaluating systemic durvalumab + intraperitoneal ONCOS-102 in patients with peritoneal disease originating from ovarian or colorectal cancer, will be presented at the ASCO (Free ASCO Whitepaper)20 Virtual Scientific conference, 29-31 May 2020 (Press release, Targovax, MAY 6, 2020, View Source [SID1234557182]). The trial is a collaboration with Cancer Research Institute (CRI) and Ludwig Cancer Research (Ludwig, trial sponsor) and AstraZeneca.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract will be released on 13 May on View Source

Abstract title:

Phase I/II study to evaluate systemic durvalumab + intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase I clinical and translational results.

Abstract no.:

3017

Presenter:

Dmitriy Zamarin, MD, PhD

On May 6, 2020 Medivir AB (Nasdaq Stockholm: MVIR) reported that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to MIV-818 for the treatment of patients with hepatocellular carcinoma (HCC), the most common type of primary liver cancer (Press release, Medivir, MAY 6, 2020, View Source [SID1234557181]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

FDA grants orphan status to drugs intended to treat rare diseases affecting fewer than 200,000 people in the U.S. The orphan designation provides certain benefits to drug developers, including tax credits for clinical trial expenditures, waived user fees for marketing applications, and eligibility for seven years of marketing exclusivity.

"It is very satisfying that MIV-818 has received a positive opinion on orphan medicinal drug designation by EMA and has been granted orphan drug designation by the FDA for the treatment of HCC", says Uli Hacksell, CEO at Medivir.

For further information, please contact:
Dr Uli Hacksell
CEO
Medivir AB
phone: +46-(0)8-5468-3100.

Medivir AB is obliged to make this information public pursuant to the EU Market Abuse Regulation.

The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 6 May, 2020.

About hepatocellular carcinoma

HCC represents the fifth most common cancer worldwide but is a rare disease in Europe and the US. Although therapies exist, treatment benefits for intermediate and advanced HCC are low and death rates remain high. HCC is a very diverse disease with multiple cancer cell types and without the tumor-specific mutations. This has contributed to the lack of success of molecularly targeted agents in HCC. The limited overall benefit, taken together with the poor overall prognosis for patients with intermediate and advanced HCC, results in a large unmet medical need.

About MIV-818

MIV-818 is a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. It has the potential to become the first liver-targeted, orally administered drug for patients with HCC.

On May 6, 2020 United Therapeutics Corporation (Nasdaq: UTHR) reported that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company’s business at the BofA Securities Virtual Health Care Conference 2020 (Press release, United Therapeutics, MAY 6, 2020, View Source [SID1234557180]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will take place on Wednesday, May 13, 2020, from 4:20 to 4:50 p.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at View Source under the "Investors" tab in the "Events and Presentations" section. An archived, recorded version of the presentation will be available approximately twenty-four hours after the session ends and can be accessed at the same location for 90 days.

On May 6, 2020 Arcadia Biosciences, Inc. (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional content of crops, reported that it will release its financial and business results for the first quarter of 2020 after market close on May 13, 2020 (Press release, Arcadia Biosciences, MAY 6, 2020, View Source [SID1234557179]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company has scheduled a conference call for 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss first-quarter results and the year’s key strategic achievements. Interested participants can join the conference call using the following numbers:

U.S. Toll-Free Dial-In:

+1-844-243-4690

International Dial-In:

+1-225-283-0138

Passcode:

3560919

A live webcast of the conference call will be available on the Investors section of Arcadia’s website at www.arcadiabio.com. Following completion of the call, a recorded replay will be available on the company’s investor website.